Safety and Efficacy of Nemolizumab in PN
NCT03181503
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
70
Enrollment
INDUSTRY
Sponsor class
Conditions
Prurigo Nodularis
Interventions
DRUG:
CD14152 Dose A
DRUG:
CD14152 placebo
Sponsor
Galderma R&D